



မှူးယစ်ဆေးစွဲကုသရေးနှင့်သုတေသနဌာန

နှစ်ပတ်လည် အစီရင်ခံစာ ၂၀၁၇ ခုနှစ်

t w d m u f s m ;	
e d f	1
r o ' y i ;	3
& n r e ; c u r s m ;	7
2017 c e p a q ; u o r c , o r s m ; t e u v i , r s m ; e i t j c m ; a o m	9
1/ a q ; p u o a & ; v y i e ; r s m ;	9
2/ r u o ' ; t p m ; x ; u o r	16
3/ r u o ' ; t p t p o e i a y i ; p y v y u i a o m o e a q m i r r s m ;	24
4/ t p n ; t a o ; e i t v y 1/2 a q ; E ; y r s m ;	27
5/ p r ; a q m i & n j r i w i a y ; j c i ;	28
6/ o a w o e a q m i & u c s u r s m ;	30
o u q i & m t z t p n ; r s m ; e i y a y i ; a q m i & u j c i ;	31
e d s y f	33
a e m u f u f w G	
1/ u e ; r m a & ; e i t m ; u p m ; O e l u ; X m e r x w i y e c a o m t r e e i a l u m j i m p m r s m ; t u s O ;	34
2/ r ; , p a q ; o ; o r s m ; q i & m v y i e ; t z \ z p n ; y e i v y i e ; w m O e r s m ;	35
& n f i e r c u f s m ;	37
y k t ;	
y (1) 2017 c e p a q ; u o r c , o r s m ; t e u v i , r s m ; e i t j c m ; a o m	12
t o u t y p r s m ; a w j r i & y	
y (2) b e ; j z l 2 b e ; r e i p w u a q ; o ; p o r s m ; u a ' o t v u a w & y	13
y (3) r u o ' ; w u a u ; a o m a e & m r s m ; e p t v u w ; c s v m y	19
y (4) 2006 r 2017 t w i ; r u o ' ; a q ; c e ; t a & t w u t v u v e m w ; w u v m y	20
y (5) j r e r m e i i t w i ; r u o ' ; w u a u ; a o m a ' o t v u v e m t i t m ; j y y	21
y (6) r E a v ; w i ; a ' o i u ; w i r u o ' ; a o m u o ; o r s m ; u a e & m t v u a w & y	22
y (7) u c s i j y n e , t w i ; & r u o ' ; a o m u o ; o r s m ; u a e & m t v u a w & y	22
y (8) & r ; j y n e , t w i ; & r u o ' ; a o m u o ; o r s m ; u a e & m t v u a w & y	23
y (9) p p u i ; w i ; a ' o i u ; t w i ; & r u o ' ; a o m u o ; o r s m ; u a e & m t v u a w & y	23
y (10) r ; , p a q ; x ; o ; p o r s m ; t l u m ; t y c t i A j z p y m ; r u a w j r i & y	25

Z, m; rsm;

Z, m; (1)	aq;uoa& t z zpn;y	4
Z, m; (2)	aq;puoa&Xmei u;rsm;? Xmei , rsm;eiruo';ay;aomaq;ce;rsm;	9
Z, m; (3)	2017 cepaq;uorc , orsm; u u sm;^r t &awjri&y	11
Z, m; (4)	2017 cepaq;uorc , orsm; u t ou typt v uawjri&y	11
Z, m; (5)	2017 cepaq;uorc , orsm; u o;paomaq; t r s; t pm; t v uawjri&y	13
Z, m; (6)	2017 cepaq;uorc , orsm; u aq;o;pyen;vr; t v uawjri&y	14
Z, m; (7)	2017 cepaq;uorc , orsm; u yn m t &n t ci; t v uawjri&y	14
Z, m; (8)	2017 cepaq;uorc , orsm; u t vyt u i t v uawjri&y	15
Z, m; (9)	2017 cepwi aq;½wua&m u u oray;i;	16
Z, m; (10)	2017 wi ruo';aomuo;orsm;	17
Z, m; (11)	ayi;pyvyaq miaom vyie;rsm; \ aq mi&uc:ur sm;	25
Z, m; (12)	r; , paq;puoa&Ei oawoeXme t aeji jyl vycaom oiwe;rsm;	28



twuufokEef

AHRN	Asian Harm Reduction Network
BI	Burnet Institute
DTC	r; , paq;pu oa&Xme
CCDAC	r; , paq;0;Ei pwuajym;vapaomaq;0;rsm; tE&m,wm;q;umu , a&A[t z
DUWG	Drug User Working Group (r; , paq;o;porrm;q i&mvyie; t z)
HPA	Health Poverty Action
ICCE	International Centre for Credentialing and Education of Addiction Professionals
Major DTC	aq;pu oa&Xme;u;
MANA	Myanmar Anti-Narcotics Association (jrermei r; , paq;0;qeusi a& t o i;)
MDM	Médecins du Monde
Minor DTC	aq;pu oa&Xmei ,
MMT	Methadone Maintenance Therapy
NAP	National AIDS Programme (t r; , om;ccu^umv om;a&m*WUZU a&Xme)
PSI	Population Services International
PWID	People Who Inject Drugs (r; , paq;x;o;porrm;)
SARA	Substance Abuse Research Association (papwwaomaq;0;rsm; qi&m oawoe t z)
UNODC	United Nations Office on Drugs & Crime (u v o r*r; , paq;0;ei jyrqi&m1/2;)
UNAIDS	Joint United Nations Programme on HIV/AIDS
UNOPS	United Nations Office on Project Services
WHO	World Health Organization (urmu;e;rma& t z)

r; , paq;0; o;pron urmaywiw;ym;vmaeaom jy ó emwpcjzply; r; , paq;0; o;pralumi
Eii t rsm; t jym;wi use;rma&;? vra&;eip;ym;a&;jy ó emrsm;cpm;ae&ay&m eii \ z \z\w;wur
u xcuapaom jy ó emwpcvn; jzpyon/ u vor* r; , paq;0;Ei jyrqi&m½; \ t p&ic
pmrsm; t & 2016 cepwi wurmv;ü r; , paq;0; o;poay;i; 247oe;ce&y; 2017 cEpt p&ic
pmwi 255 oe;&alumi;azmjyxm;onu awEiyon/ t qy½; \ t p&icpm t &vn; r; , p
aq;0; o;pralumi q;u s;cpm;&oay;i;rmvn; 2016 cEpwi 28.7oe;&c&mr 2017 cepwi
29.5 oe; t x w;vmcalumi;aw&yon/

jrrmEii taejivn; w&m;r0ir; , paq;0;rsm; zr;q;&ron w;wu vmaomalumi r; , p
aq;0;jy ó emon w;ym;vmaeonu cere;Eiyon/ r; , paq;0;Eipwuaajmi;vapaom
aq;0;rsm; t E&m , wm;q;umu , a&;A [t z \Epywvn t p&icpm t & 2016 cepwi be;jzl
769.26 uv*&r (2015wi 186.04 uv*&r) Ei pw:uaq;jym; 98.35 oe;ausm (2015 wi
49.5 oe;ausm) zr;q;&rcojzi² r; , paq;0;jy ó emi u;xm;vmaealumi; xi [yaeyon/

r; , paq;puoa&;EioawoeXmeu 1976 cepwi pwiwnaxmicly; r; , paq;0;e , y ,
wi ajmi;vrrsm;jzpay:vmonEi t r l vyie;aq;miwrm;vn; wjzn;jzn; w;wuajmi;v
vm cyon/ pwi í wnaxnip0u r; , paq;puoa&;uom t "u vyuic&mr r; , paq;
x;o;pjci;alumi t u s;qu taeji vx use;rma&;jy ó emrsm;vn; ayayuvmcyon/ use;
rma&;Xme \ t r s;om;ccus^umvom;a&m* q wuzua&;Xmer t ycs t iAq i&m Epp0 apmilun
í ao;azmupp aq;r t & 2008 cEpwi r; , paq;u talumwi;o x;oi;o;porsm; t lum;ü
jzpy;Ee; 37.5% &aeonu aw&y; , i;on t jcm;aom t E&m , &aom v typrsm; t lum;
wi u;pur t jirm;q;jzpaeyon/ t qy; 2008 cEpt p&icpmüyi ao;azmupp aq;aom
a'o t v u r; , p aq;x;o;porsm; t lum;wi aw&&onrm vm;½;ü 37.4%? rEav;ü 37%?
jrpu;em;ü 54.5% Ei rq , ü 43.3% &aeonu aw&yon/³ t qy t a jct aersm;alumi
t E&m , avsmusa&; prcsu rsm;u r; , paq;0; o;prrrsm;aom a'orsm;wi taumit x nazm
vmcluyon/ jrermEiwi r; , paq;x;o;porsm;on be;jzlu t "uo;pluaomalumi
r; , paq;puoa&;EioawoeXmeon 2006 cEpwi urmuse;rma&; t z \yy;rzi be; t pm;
x;uorjzpaom ruo' ;wu aut;uoru &eue? rEav;? vm;½;eiirpju;em;r rsm;wi pwi
pr;oytaumi t x nazmcyon/

tycstiaU;pua&m*tiyi aorwpqiu;pueiaom a&m*irms;jzpon toa&mia&m*irms;
onvn; trsm;jynotwu tE&m , &vmay&m r; , paq;x;o;porsm; twuvn; p;r
&aom vxuse;rma&jy óenjzpvncyon/ xajumi r; , paq;puoa&ei oawoeXmeon
ai;\ vyie;irms;wi toa&mia&m*y; &r&ppaq;ji;Ei toa&miby; umu , aq; x;eay;
ji; vyie;irms;uyiw;csvyaqmi vmcyon/

2009 cepwi uvor*tztpn;irms;u r; , paq;x;o;porsm;qi&m bupvr;ji aom Oe
aqmirrms;^u xwyéalunmay;cy;? jrermEii ccu?^umvom;a&m*wuzua&Xmeu vn;
2014 cepwi xwa0aom JjermEii& t"uv typrsm; tlu m; tycstiaumu , a& twu
t"u Oeaqmirrms;} [í tvm;wyi xwyecyon⁵/ bupvr;ji aom Oeaqmirrms;on
ta&twu t m;ji (9)c&y; jrermEii ccu?^umvom;a&m*wuzua&Xmeu vn; twwyi
Oeaqmir (9)c ovrwxm;yon/ tqy Oeaqmirrms;wi be; tpm; x;uorei civaom
taxmutxm;u tajccon r; , paq;puorrrsm;? toa&mia&m*umu , ji;? umu ,
aq;x;Eji;? a&m*y; &r&ppaq;ji;Ei uoay;ji;wy0iyon/

vu&taejziqvsi jrermwpEii v;wi r; , paq;puoa& Xmeu;ay;i; (26)c? Xmei , ay;i;
(47)c? ruo'e;wuau; aomaq;ce;ay;i;(51)c tx&om;ijzpyon/ r; , paq;puoa&ei
oawoeXmeon ruo';wuau; aom tptp0u uvor*tztpn;irms;? ccu?^umvom;
a&m*wuzua&Xme;jynwi;jyny tp;&r [waom tztpn;irms;Ei vuwí taumitxn
azmaqmi&uvu&yon/

r; , paq;0; o; pron urmei t0e; ulawae&aom jy ó emizponei t rs p0quriyw z lz;
w;wua&; q i&m &nre; c uye; wirsm; u 2030 t xcrwxm; &mw i r; , paq;0; ei ywou í
vn; xn oi; x m; cluyon/ ye; wi t rw3 u]ou& , ra&; vwi; ap use; rma&; ei om , m0
ajyma&; } [c rwxm; y; ? t qy ye; wiat muwi t rw 3.5 ü]r; , paq;0; o; prei t&uu
t E&m , jzpat miaom uo; ci; w ty t0i r; , paq;0; rsm; t vo; ru umu , jci; Ei uo ci;
u yr t m; aumi; a t mi vyaq mi ay; &e } [c rwxm; cluyon/ ou q i&m t ñe; ue; (3.5.1)
t aeji vn;]r; , paq;0; o; pralum i jzpaom q; u s; rsm; u uoay; aom vyie; rsm; (aq; uo
r? pw use; rma&; ? jye vn xax mia&; Ei aem u quw ap mia&m ur vyie; rsm;) \ vr; jci eir }
[íowrwxm; onu aw jriei yon/

j rerm Ei ion u vor* \ r; , paq;0; q i&m ue Ai; &i; rsm; u oabmwv urwa&; x; x m; aom
t z0i Ei i jzponei t n 1993 cEp]r; , paq;0; Ei pwuajymi; vapaom aq;0; rsm; q i&m
Oya' u j yXme; cly; t qy i Oya' u , c t c; acw Ei t n jye vn yi q iaeq jzpyon/ j rerm
e i i taezi 2017 cepwi t r s; om; r; , paq;0; x e; c sly a&; q i&m r0; ' u a&; q cly; t qy; r0; '
t & r; , paq;0; jy ó em u use; rma&; t av; ay; c s0; uy vyaq mi r zi v yu i om; r n jzpyon/
x or0; ' a&; q &mw i vn; r; , paq; pu oa&; ei oawoe Xme t aezi y; ay i; y0i vyaq mic
yon/ t qy; r0; ' t & ty i; 4 yi; y&y on-

- xwvyrav sm u a&; ei t pm; x; z lz; a&; /
- o; prav sm u a&; ei t E&m , av sm u a&; /
- ei iwum y; ay i; aq mi &ua&; /
- oawoe Ei c jr; pwjz mav v mr/

r; , paq;0; Eipwuajymi; vapaomaq;0; rsm; t E&m , wm; q; umu , a&; A [t zon 1993
cep r; , paq;0; Eipwuajymi; vapaomaq;0; rsm; q i&m Oya' y i j yXme; c s ur sm; Ei t n ou
q i&m vyie; t z r sm; zpn; cly; 2016 cEpwi j y i q izpn; caom aq; u oa&; t z r m° wpzuy
t wi; jzpyon/

Z , m; (1) aq;u oa&; t z zpn;y

p0	u , pm;jylo	0e!u;Xme^Xme	&m x;
1/	t jrwr; t wi;0e	use;rma&;Ei t m;upm;0e!u;Xme	0u
2/	'w , ñe!um;a&;rl;c!y	t axax tyc!ya&;0;p;Xme jyn x a&;0e!u;Xme	t z0i
3/	'w , ñe!um;a&;rl;c!y (a&m*;ErEi;a&;)	jynouse;rma&;0;p;Xme use;rma&;Ei t m;upm;0e!u;Xme	t z0i
4/	'w , ñe!um;a&;rl;c!y (u oa&;)	u oa&;0;p;Xme use;rma&;Ei t m;upm; 0e!u;Xme	t z0i
5/	'w , ñe!um;a&;rl;c!y	vr0exr;0;p;Xme vr0exr;? u , q , a&;Ei jyev nae&m;c;x m;a&; 0e!u;Xme	t z0i
6/	Xmerl;	prue;Xme r; , paq;0;wm;q;ErEi;a&;&wyz	t z0i
7/	0u uwm0eay; t yaom ynm&i t x;u q&m0e!u; wp0; (r; , p)	u oa&;0;p;Xme use;rma&;Ei t m;upm;0e!u;Xme	t z0i
8/	wm0ecq&m0e!u;^ prc;u reae*sm	pwuse;rma&; aq;½u;? &euclr/ use;rma&;Ei t m;upm;0e!u;Xme	t z0i
9/	ñe!um;a&;rl;c!y	u oa&;0;p;Xme use;rma&;Ei t m;upm;0e!u;Xme	t wi;a&;rl;

t realumjimpn trw 3^2016 t & aq; uoa& ; t z\ vyie;wm0ersm;rm a t m uy; t wi; jzpy;
on -

- 1/ aq; uoa& ; vyie; rsm; xa& m uat mijripma qmi& uei& e r0j' ? ye; wiei & nre; csm; cswjci; ?
- 2/ r; , paq; pjci; u jzpayapon talumi; & i; rsm; ei r; , paq; pa& m* jyeym; ru avvm jci; (Epidemiology of drug use disorders) ? r; , paq; 0; t alumi; x; o i; on vent a& t wu u cere; jci; (Population size estimation for people who inject drugs) ? r; , paq; o; p orsm; \ t jyl t rei a& m* jzpy; Ee; u ayi; pyavvm qe; ppjci; (Integrated biological and behavioural survey) ? t raxmipt v u pp wr; aumu , jci; (Household survey) ? pmoia u smi; rsm; wi r; , paq; 0; o; prqi& m ppwr; aumu , jci; (School survey) pon avvm qe; ppr ppwr; aumu , jci; vyie; rsm; aqmi& ujci; ?
- 3/ r; , paq; 0; ei pwuajymi; vapoam aq; 0; rsm; o; pjci; ei aemuquw t E& m , jzpy; rqi& m p0quriyw apm iluyq; pponpepwp& ywnaxmi jci; ?
- 4/ avvm qe; ppr rsm; \ aw& c; ur sm; tay: t ajccí umu , uoa& ; ei t E& m , avsm uoa& ; qi& m prue; rsm; a& ; q taumi t xnazm aqmi& ujci; ?
- 5/ aq; uoa& ; vyie; rsm; taumi t xnazm aqmi& u& mwi vtyaom taxmu ty t ut nrsm; & & ei& eei at mijripma qmi& uei& e E; E , Xmersm; ? uvor* tz t pn; rsm; ? t p; & r [waom tz t pn; rsm; Ei ayi; pynEi; aqmi& ujci; ?
- 6/ be; ^ be; jzl^ pwu 1/2; oyaq; rsm; t jyi xyray: xuvmon pwajymi; aq; 0; oprsm; ei ywouaom u x; rsm; t m; acwei t n & apa& ; p0quriyw avvm jci; ? uoay; jci; ei uor& v' qi& m oawoeaqmi& ujci; ?
- 7/ r; , paq; p uoa& ; q& m 0ersm; \ vyie; pr; & n jriwia& ; oiwe; (Capacity building) ei r; ; quopq& m 0ersm; ar; xway; a& ; aqmi& ujci; ?
- 8/ r; , paq; pvem rsm; aq; uor vuvr; rapa& ; twu r; , paq; pa& m* j uoa& ; Xmersm; w; c; izvpay; jci; Ei uoa& ; Xmersm; u t qijriwi jci; ?
- 9/ jynovx t ajcyl r; , paq; puoa& ; vyie; qi& m vr; ñe; jypjci; ? oiwe; rsm; aqmi& ujci; Ei E; E , Xmersm; Ei nEi; um vuaw taumi t xnazm aqmi& ujci; ?
- 10/ r; , paq; 0; o; pralumi jzpay: vmon aemuquw q; u; t E& m , av; mca& ; r0j' a& ; qly; vyie; rsm; taumi t xnazmaqmi& ujci; ?
- 11/ r; , paq; 0; t E& m , toynmay; vyie; rsm; u E; E , vyie; t zrm; ei ayi; pyaqmi& ujci; ?

- 12/ aq;uorc , ly;or_{sm}; jyevnxaxmia&t_{wu} ouqi&_m t_{zr}_{sm};ei ayi;pynEi;
aqmi&ujci;?
- 13/ aq;uoa& vyie;_{rsm}; at mijrip_m taumi t x nazmaqmi&uEia&ouqi&_{mwi};
a'o_{lu};^lyne , ^aejynawmjynaxmipe , a_{ru}oa& O;p;Xmerl;_{rsm};u te;uy _{lu};
luyaqmi&u&e pp0ñel_{um};jci;ei v tyc_{ur}_{sm}; wijyv_{mr} tay. jznqn;aqmi&u
jci;?
- 14/ prue;vyie;_wwur tp&icp_{mu} t c_i t_m;av_{sm}p_m A [tzo wiyjci;?
- 15/ aq;uoa&vyie;_{rsm}; taumi t x nazmaqmi&_{ur} t ajc taet_m; qe;ppo;oy
aqmi&ujci;?
- 16/ aq;uoa&prue;vyie;_{rsm}; taumi t x nazm aqmi&u&_{mwi} b@mai u_{co};pr
t_m; prcecjci;? _{lu};luyjci;ei wi;a'o_{lu};^lyne , b@mair u_{co};prnqy_{uvn};
vyie; v tyc_{ur}_{sm};Ei t n &apa& prcecayjci;/

r; , paq;puoa&Ei oawoeXmeon ajymi;vvmaom taictaersm;Ei vyie;aqmi&u
c:ursm; t & 2017 cepwi &nre;cursm;u jyi qicyon/

- 1/ ppn;ayi;pyx;m;aom? qe;opwxir&aom? um , u&i\qEtavsmujzply; bup
vr;jclr&on aq;uoa&vyie;rsm;\ t&n tao;w;wuaumi;reap&e?
- 2/ emwm&ncpm;&um uorc , ly;yuvn; jyevnizpym;wwaom r; , paq;pji;u we
jyeaqmi&urrs; yrw;wuaumi;reap&e twu p0quriyw apmia&murujriwi
ay;&e?
- 3/ bupvr;jclr&aom vx t aicjy/aq;puoa&vyie;rsm; azmaqmi&mwi t m;ay;jriwi
ay;&eei yy;un&e?
- 4/ r; , paq;puorvyie;rsm; w;wuaumi;revmapa& twu ayi;pynEi;r? y;ayi;
aqmi&urei pr;aqmi&njriwiay;jci;rsm;u yr t m;aumi;cirmvmap&e?
- 5/ bupvr;jclr&aom r; , paq;puoa&vyie;rsm; w;wujzpayvmap&e taxmu
t x m; ci von vyen;vy[ersm;u oawoejyvy&Ei aw&vmaom r[mAdL[m
ajrmu owi;t cu t vursm; rla0r yr t m;aumi;vmap&e/



Zev 26 &uae t cr; t em;wi ' - orw vma&mulun½p0



r; , paq;puoa&EioawoeXmejy; t m; use;rma&Ei
t m;upm;0eiu; vma&m ulu n½p0



t mp , t q ijr i t &m&u;rsm; \ r; , paq;0;ijy ó em rsm; q i&m
38 iurajrm u t pn; ta0;u A , uerEi iwi usi;yp0

vkfafaqmitafufsm; (2017)

1) aq;puo&;vkfafaqmitafufsm;

aq;puo&; Xmei;u;rm;? Xmei , rm;ei ruo';wuau;aom aq;ce;rm;u at mu;twi;
awjrieiyon-

(Z , m; 2? aq;puo&;Xmei;u;rm;? Xmei , rm;Eiruo';ay;aomaq;ce;rm;)

p0	jyne , ^wi; a'oiu;	Xmei;u;rm; (Major DTC)	aq;puo&;Xmei , rm; (Minor DTCs)	ruom';aq;ce;rm; (MMT Sites)
1/	&eue	&eue	-	&eue (2)
2/	rEav;	rEav;	ji0;vi? r;uw? y0;rem? jri;jc (4)	rEav;? ji0;vi r;uw (4)
3/		rwvm		
4/		ausmuqn		
5/	ppui;	r&m	[r;rvi;? x;c;i? cE; uebv? ti;awm? uom? 0e;o? ule;v? yivnb? Ae;arm? aumvi;? wr; a&b? armvu (14)	ppui;? r&m? uav; wr? aumvi; yivnb;? uom? Ae;arm? ti;awm? [r;rvi;? cE; aemiya? mi? armv; azmi;ji (14)
6/		uav;		
7/	uci	jrpl;u;em;	r;aumi;? r;ni;? zm;ue? 0i;arm? r;armu? ywm t (6)	jrpl;u;em;? Ae;arm? atmi;riom? 0i;arm? r;aumi;? erw; [yi? r;ni;? caz? zm;ue? qyr? v;ci; rep? r;armu? a&u/ (15)
8/		Ae;arm		
9/	&r; (t a&)	usi;w	ri;qw? ri;a , mi;? ri; , e; ri;jzw? wmc;vw (5)	wmc;vw (1)

10/	&r; (ajrmu)	v m;½;	uev? uwci? ausmur? avmu ui? rew? re;u;? r;rw? rq , ?ercr;? erqe? yeqi; (11)	v m;½;? oe;e? uwci? erzwum? r q , ? ercr;? ausmur? wmr;n? erw;? eray;i? we , e;? erqe? oay? aemici? r;rw (15)
11/	&r; (awmi)	awmi;u;	uavm? ue [e;? ri;½;? eeqe (4)	-
12/		v , v i		
13/	{&m0w	yor	-	-
14/		[omw		
15/	yc;	yc;	om , m0w (1)	-
16/		jyn		
17/		awmi i		
18/	cs; i;	[m;C;	-	-
19/	u&i	bm; t	jr0w (1)	-
20/	u , m;	v liaum	-	
21/	rau;	rau;	-	-
22/		ycul		
23/	re	armviri	-	-
24/	&ci	ppaw	-	-
25/	weom&	x m;0 ,	aumaomi; (1)	-
26/		lrw		
	ppay;i;	26	47	51

2017 ခုနှစ် မြို့နယ် အဆင့် စာမေးပွဲ ရလဒ်များ

2017 ခုနှစ် မြို့နယ် အဆင့် စာမေးပွဲ ရလဒ်များ (မြို့နယ် ၁)


ကျား/မ	ရန်ကုန်	မန္တလေး	စစ်ကိုင်း	ကချင်	ရှမ်း (အရှေ့)	ရှမ်း (တောင်)	ရှမ်း (မြောက်)	ပဲခူး	မွန်	ကရင်	တနင်္သာရီ	စုစုပေါင်း	%
ကျား	၉၂၉	၈၉၁	၁၄၂၈	၂၄၆၉	၂၃၉	၁၀၂	၆၅၆	၁၂၉	၇၂	၁၀၄	၄၁၂	၇၄၁၁	၉၈.၆၁
မ	၂၉	၂	၈	၃၅	၁၆	၁	၁၃	၀	၀	၀	၁	၁၀၅	၁.၃၉
စုစုပေါင်း	၉၅၈	၈၉၃	၁၄၃၆	၂၅၀၄	၂၅၅	၁၀၃	၆၆၉	၁၂၉	၇၂	၁၀၄	၄၁၃	၇၅၁၆	၁၀၀

2017 ခုနှစ် မြို့နယ် အဆင့် စာမေးပွဲ ရလဒ်များ (မြို့နယ် ၂)

အသက်အုပ်စု	ရန်ကုန်	မန္တလေး	စစ်ကိုင်း	ကချင်	ရှမ်း (အရှေ့)	ရှမ်း (တောင်)	ရှမ်း (မြောက်)	ပဲခူး	မွန်	ကရင်	တနင်္သာရီ	စုစုပေါင်း	%
၁၀-၁၄	၃	၂	၀	၁	၀	၀	၃	၀	၀	၀	၀	၉	၀.၁၂
၁၅-၁၉	၉၂	၇၇	၃၄	၈၃	၁၅	၃	၁၆	၁၆	၂၂	၁၂	၃၂	၄၀၂	၅.၃၄
၂၀-၂၄	၂၇၈	၂၅၄	၂၀၂	၅၅၉	၄၁	၂၂	၈၆	၄၂	၂၁	၂၅	၈၂	၁၆၁၂	၂၁.၄၁
၂၅-၂၉	၂၃၅	၂၁၁	၂၇၅	၅၄၉	၃၀	၂၄	၁၁၂	၄၄	၁၀	၂၀	၁၀၇	၁၆၀၇	၂၁.၃၄
၃၀-၃၉	၂၆၇	၂၃၁	၅၉၁	၈၆၈	၇၉	၂၉	၂၃၁	၂၁	၁၅	၃၆	၁၂၈	၂၄၉၆	၃၃.၁၅
၄၀-၄၉	၇၆	၉၅	၂၆၄	၃၄၉	၅၁	၁၅	၁၄၀	၅	၄	၈	၆၁	၁၀၆၈	၁၄.၁၉
၅၀-၅၉	၇	၃၀	၆၆	၁၀၀	၃၅	၁၀	၇၁	၁	၀	၃	၇	၃၃၀	၄.၃၈
၆၀ အထက်	၀	၃	၄	၉	၄	၀	၁၀	၀	၀	၀	၀	၃၀	၀.၄၀
စုစုပေါင်း	၉၅၈	၈၉၃	၁၄၃၆	၂၅၀၄	၂၅၅	၁၀၃	၆၆၉	၁၂၉	၇၂	၁၀၄	၄၁၃	၇၅၁၆	၁၀၀

2014 cEpwi aumu , aom oe;ac;ipm&i; t& uav;oi , (0-14 Ep) 0;a&on 14.4 oe; (v0;a&\ 29%) &y; vi , (15-24 ep) rsm; on 9 oe; (v0;a&\ 18%) &y; tqyvi , 0; a&on usqi;om;rn [cere;xm;onu aw&y;on7/ vi , rsm; on Eii\ tem*wtwu tz;we t&i;tjrprsm;jzpon t m;avsm 2017 cEpwi r; , paq;puo&e vma&m uor sm; t eu vi , rsm; \ t ajc taeu at mu y;twi; aw jriEiyon -

yk) 2017 cEpwi r; , paq;puo&e vma&m uor sm; t eu vi , rsm; \ t ajc taeu at mu y;twi; aw jriEiyon -




vi , rsm; (15-24 Ep) on 2017 wi ppay;i; vma&m uaq;uo oay;i; \ 27.97% &onu aw jriEiyon/

2017 ခုနှစ် ဇန်နဝါရီလ ၁ ရက်နေ့မှ ဇူလိုင်လ ၃၀ ရက်နေ့အထိ နယ်လုံးဆိုင်ရာ စစ်ဆေးမှု ရလဒ်များ

အမျိုးအစား	ရန်ကုန်	မန္တလေး	စစ်ကိုင်း	ကချင်	ရှမ်း (အရှေ့)	ရှမ်း (တောင်)	ရှမ်း (မြောက်)	ပဲခူး	ဗန်းမော်	ကရင်	တနင်္သာရီ	စုစုပေါင်း	%
သိန်းဖြူ	၃၅၉	၈၅၅	၁၃၇၄	၂၄၈၇	၁၀၆	၁၉	၆၄၄	၅၁	၁၉	၁၇	၅	၅၉၃၆	၇၈.၇၇
သိန်းမဲ	၃၀	၂၀	၆၁	၁၆	၈၄	၇၅	၂၀	၄	၆	၀	၃	၃၁၉	၄.၂၃
ဆေးကြောက်	၂၁	၁	၀	၀	၀	၀	၀	၁	၀	၀	၀	၂၃	၀.၃၁
စိတ်ငြိမ်ဆေး	၀	၀	၀	၀	၀	၀	၀	၃	၀	၀	၀	၃	၀.၀၄
စိတ်ကြွဆေး	၅၃၈	၁၇	၁	၀	၆၄	၉	၅	၇၀	၄၆	၈၇	၁၄၆	၉၈၃	၁၃.၀၄
အခြား	၁၀	၀	၀	၁	၁	၀	၀	၀	၁	၀	၂၅၉	၂၇၂	၃.၆၁
စုစုပေါင်း	၉၅၈	၈၉၃	၁၄၃၆	၂၅၀၄	၂၅၅	၁၀၃	၆၆၉	၁၂၉	၇၂	၁၀၄	၄၁၃	၇၅၃၆	၁၀၀

2017 ခုနှစ် ဇန်နဝါရီလ ၁ ရက်နေ့မှ ဇူလိုင်လ ၃၀ ရက်နေ့အထိ နယ်လုံးဆိုင်ရာ စစ်ဆေးမှု ရလဒ်များ



2017 ခုနှစ် ဇန်နဝါရီလ ၁ ရက်နေ့မှ ဇူလိုင်လ ၃၀ ရက်နေ့အထိ နယ်လုံးဆိုင်ရာ စစ်ဆေးမှု ရလဒ်များ

t xuyyt& ucsi? ppui? &rjyne , Ei rEav;wi;a'o'u;wwi be;jzlo;pci;t wu
uorc , o yrrsm;y?;pwuaq; o;pci;alumi aq;uorc , orsm;u &euwei;a'o'u;wi
trsm;qawjri&y on/

2017 ခုနှစ်၊ ဇန်နဝါရီလ ၁ ရက်နေ့မှ ဇူလိုင်လ ၃၀ ရက်နေ့ (၆၊ ၆)

သုံးစွဲသည့် နည်းလမ်း	ရန်ကုန်	မန္တလေး	စစ်ကိုင်း	ကချင်	ရှမ်း (အရှေ့)	ရှမ်း (တောင်)	ရှမ်း (မြောက်)	ပဲခူး	မွန်	ကရင်	တနင်္သာရီ	စုစုပေါင်း	%
မျိုးစား	၂၃	၁၂	၃၀	၉	၂၁	၄၃	၈	၁	၈	၀	၂၆၂	၄၁၇	၅.၅၃
ရှုမြင်း	၆၈၆	၁၆၈	၁၇၇	၂၂၅	၁၆၅	၅၀	၂၃၇	၈၈	၆၀	၇၅	၁၃၈	၂၀၆၉	၂၇.၄၅
အကြောင်း	၂၄၆	၇၁၁	၁၂၂၉	၂၂၆၉	၆၉	၁၀	၄၁၅	၄၀	၄	၂၉	၁	၅၀၂၃	၆၆.၆၅
ရှုပ်	၀	၂	၀	၀	၀	၀	၉	၀	၀	၀	၀	၁၁	၀.၁၅
အခြား	၃	၀	၀	၁	၀	၀	၀	၀	၀	၀	၁၂	၁၆	၀.၂၁
စုစုပေါင်း	၉၅၈	၈၉၃	၁၄၃၆	၂၅၀၄	၂၅၅	၁၀၃	၆၆၉	၁၂၉	၇၂	၁၀၄	၄၁၃	၇၅၃၆	၁၀၀

2017 ခုနှစ်၊ ဇန်နဝါရီလ ၁ ရက်နေ့မှ ဇူလိုင်လ ၃၀ ရက်နေ့ (၆၊ ၆)

ပညာ အရည် အချင်း	ရန်ကုန်	မန္တလေး	စစ်ကိုင်း	ကချင်	ရှမ်း (အရှေ့)	ရှမ်း (တောင်)	ရှမ်း (မြောက်)	ပဲခူး	မွန်	ကရင်	တနင်္သာရီ	စုစုပေါင်း	%
စာမတတ်	၄	၇	၈	၂၀	၈၅	၈၅	၄၉	၀	၀	၄	၁၈	၁၉၅	၂.၅၉
ဘုန်းကြီးကျောင်း	၂	၅	၁၆	၁၈	၆	၆	၁၄	၂	၁	၂	၄၆	၁၄၃	၁.၉၀
မူလတန်း	၄၀	၁၄၁	၅၇၄	၇၃၆	၅၈	၅၈	၂၂၇	၄၂	၂၈	၂၉	၁၂၆	၂၀၀၆	၂၆.၆၂
အလယ်တန်း	၂၁၁	၂၉၉	၅၀၉	၉၀၇	၅၅	၅၅	၂၁၆	၅၀	၂၈	၃၇	၁၄၄	၂၄၇၃	၃၂.၈၂
အထက်တန်း	၄၇၅	၂၈၅	၂၇၈	၆၄၃	၄၃	၄၃	၁၂၇	၃၅	၁၁	၂၆	၇၂	၂၀၂၆	၂၆.၈၈
တက္ကသိုလ်	၁၄၈	၁၀၄	၄၀	၁၁၀	၄	၄	၁၉	၀	၄	၆	၁	၄၄၄	၅.၈၉
အခြား	၇၇	၅၁	၁၁	၂၂	၃	၃	၁၅	၀	၀	၀	၆	၁၉၆	၂.၆၀
စုစုပေါင်း	၉၅၈	၈၉၃	၁၄၃၆	၂၅၀၄	၂၅၅	၂၅၅	၆၆၉	၁၂၉	၇၂	၁၀၄	၄၁၃	၇၅၃၆	၁၀၀

2017 ခုနှစ် ဖောက်ဖျက်မှုများကို စစ်ဆေးရာတွင် (26.88%)၊
 တစ်စိတ်တစ်ဒေသ (32.82%)၊ အခြား (26.62%) ဖြစ်ပါသည်။

2017 ခုနှစ် ဖောက်ဖျက်မှုများကို စစ်ဆေးရာတွင် (26.88%)၊
 တစ်စိတ်တစ်ဒေသ (32.82%)၊ အခြား (26.62%) ဖြစ်ပါသည်။

	ရန်ကုန်	မန္တလေး	စစ်ကိုင်း	ကချင်	ရှမ်း (အရှေ့)	ရှမ်း (တောင်)	ရှမ်း (မြောက်)	ပဲခူး	မွန်	ကရင်	တနင်္သာရီ	စုစုပေါင်း	%
တောင်သူ	၄၁	၁၁၀	၃၄၁	၆၈၂	၈၅	၄၀	၁၆၇	၅	၁၃	၁၆	၄၇	၁၅၄၇	၂၀.၅၃
ဈေးရောင်း	၈၅	၁၁၀	၈၇	၁၃၄	၄၁	၁၄	၂၄	၁၁	၂	၈	၄	၅၂၀	၆.၉၀
အနီးရပ်(ဥယျာဉ်)	၂၂	၁၆	၁၀	၂၇	၁	၁	၁၅	၀	၃	၄	၀	၉၉	၁.၃၂
ပြင်ပဥယျာဉ်	၆၁	၁၉	၄	၇	၁	၄	၉	၀	၀	၂	၆	၁၁၃	၁.၅၀
ပြင်ပကယ	၁၁၄	၂၈၆	၃၃၃	၄၆၃	၃၆	၁၇	၂၁၀	၀	၁၈	၂၈	၁၆၉	၁၆၇၄	၂၂.၂၁
ကုန်သည်	၆၁	၄၀	၃၈	၁၀၇	၅	၂	၁၅	၀	၂	၉	၁၀၁	၃၈၀	၅.၀၄
လက်မှုပညာ	၂၃	၁၇	၅	၂၁	၁	၁	၅	၀	၀	၀	၀	၇၃	၀.၉၇
ကျောင်းသား	၆၇	၃၁	၆	၁၀	၃	၂	၄	၂၅	၂	၂	၁	၁၅၃	၂.၀၃
မှီခို	၃၁၈	၁၈၅	၃၂၈	၄၆၈	၆၃	၂၂	၁၃၁	၄၂	၂၁	၁၈	၄	၁၆၀၀	၂၁.၂၃
အငြိမ်းစား	၁	၀	၁	၆	၁	၀	၀	၀	၀	၀	၀	၀	၀.၁၂
ကျွန်း	၆၇	၅၁	၂၀၃	၄၀၂	၁၈	၀	၄၂	၄၆	၇	၁၁	၈၁	၉၂၈	၁၂.၃၁
ယာဉ်မောင်း	၉၈	၂၈	၉၁	၁၇၇	၀	၀	၄၇	၀	၄	၆	၀	၄၅၁	၅.၉၈
စုစုပေါင်း	၉၅၈	၈၉၃	၁၄၃၆	၂၅၀၄	၂၅၅	၁၀၃	၆၆၉	၁၂၉	၇၂	၁၀၄	၄၁၃	၇၅၃၆	၁၀၀

အသုံးပြုသူ အမျိုးအမည်	ရက်စွဲ	မန္တလေး	စစ်ကိုင်း	ကချင်	ရှမ်း (အရှေ့)	ရှမ်း (တောင်)	ရှမ်း (မြောက်)	ပဲခူး	မွန်	ကရင်	တနင်္သာရီ	စုစုပေါင်း
ပထမအကြိမ်	၉၅၈	၈၈၉	၁၄၄၆	၂၅၀၄	၂၅၄	၁၀၃	၆၆၂	၁၂၉	၇၆	၁၀၄	၄၁၃	၇၅၂၈
ဒုတိယအကြိမ် နှင့်အထက်	၄၆၅	၅၂၇	၀	၄၃၂	၁	၂၉	၁၆၄	၀	၁	၀	၀	၁၆၁၉
စုစုပေါင်း	၁၄၂၃	၁၄၁၆	၁၄၄၆	၂၉၃၆	၂၅၅	၁၃၂	၈၂၆	၁၂၉	၇၇	၁၀၄	၄၁၃	၉၁၄၇

၂) ဝတ်စုံ

ruo'; tpm; x; aq; wuau; jci; u 2006 cEpwi pwicly; vyie; rsm; u wzn; jzn; w; c; vmc
yon/ 2017 cEpwi ruo'; wuau; aom ae&may; i; (51) t x &om; lyjzpyon/
ruo'; aq; wuau; jci; on r; , paq; u talumwi; o x; oi; o; porsm; twu t ve
ta& y; vyon/ ruo'; aq; aom u o; jci; jzi aq; x; o; porsm; on tyc; t iAEiwu ao; r
wpqi u; puap Eiaom t jcm; aoma&m* rsm; u; puru avmen; om; apEionomru aem u
quwvra& q; u s; rsm; u vn; avsm u om; apEi yon/ 2017 cEpwi ruo'; aom u o;
ta& twu u wpzuy; twi; awjriEi yon/


စဉ်	ပြည်နယ်/တိုင်းဒေသကြီး	မက်သဒုံးတိုက်သောနေရာ	စတင်သောအချိန်	ကျား	မ	စုစုပေါင်း
၁၂	ရန်ကုန်	ရန်ကုန်	၂၀၀၆ မတ်လ ၃/၂၀၀၆ စက်တင်ဘာ ၁၈	၅၆၀	၁၅	၅၇၅
၃၂၄	မန္တလေး	မန္တလေး	၂၀၀၆ ဖေဖော်ဝါရီ ၁၆/၂၀၀၉ မတ်လ ၁၃	၁၈၄၂	၁၉	၁၈၆၁
၅။		ပြင်ဦးလွင်	၂၀၁၃ အောက်တိုဘာ ၁	၁၃၂	၃	၁၃၅
၆။		မိုးကုတ်	၂၀၁၇	၂၀၇	၀	၂၀၇
၇။	ကချင်	မြစ်ကြီးနား	၂၀၀၆ ဖေဖော်ဝါရီ ၂၁	၆၆၈	၇	၆၇၅
၈။		အောင်မြင်သာ	၂၀၁၃ စက်တင်ဘာ ၂၄	၄၂	၁	၄၃
၉။		ဗန်းမော်	၂၀၀၇ စက်တင်ဘာ ၁၀	၆၁၅	၃	၆၁၈
၁၀။		ဝိုင်းမော်	၂၀၁၁ နိုဝင်ဘာ ၁၀	၃၁၂	၁	၃၁၃
၁၁။		မိုးကောင်း	၂၀၀၇ ဇွန်လ ၂	၅၆၁	၁၀	၅၇၁
၁၂။		နမ္မတီး	၂၀၁၀ ဩဂုတ် ၁	၃၀၁	၂	၃၀၃
၁၃။		ဟိုပင်	၂၀၁၂ စက်တင်ဘာ ၁	၅၂၄	၇	၅၃၁
၁၄။		မိုးညှင်း	၂၀၁၂ အောက်တိုဘာ ၁	515	0	515
၁၅။၁၆		ဖားကန့် ဆိပ်မူ	၂၀၁၂ ဩဂုတ် ၁၆/ ၂၀၁၃ ဩဂုတ် ၁	၁၁၀၈	၅၇	၁၁၆၅
၁၇။		လုံးခင်း	၂၀၁၄ မေလ ၁	၆၇၆	၁၀	၆၈၆
၁၈။		မန်စီ	၂၀၁၅ ဇန်နဝါရီ ၂၀	၁၀၄	၀	၁၀၄
၁၉။		ရွှေကူ	၂၀၁၅ ဇန်နဝါရီ ၂၀	၇၅	၃	၇၈
၂၀။		ချီဗွေ	၂၀၁၆ မတ်လ ၃၁	၉	၀	၉
၂၁။		မိုးမောက်	၂၀၁၆ ဇွန်လ ၁	၁၁၃	၂	၁၁၅
၂၂။	ရှမ်း (မြောက်)	လားရှိုး	၂၀၀၆ ဖေဖော်ဝါရီ ၂၀	၃၄၄	၃	၃၄၇

၂၃။		သိန်းနီ	၂၀၁၂ ဩဂုတ် ၂၄	၆၃	၁	၆၄
၂၄။		ကွတ်ခိုင်	၂၀၁၁ စက်တင်ဘာ ၁၃	၁၃၇	၁	၁၃၈
၂၅။		မူဆယ်	၂၀၁၀ ဇန်နဝါရီ ၁၉	၂၉၆	၆	၃၀၂
၂၆။		နမ့်ခမ်း	၂၀၁၁ စက်တင်ဘာ ၁၄	၂၁၂	၂	၂၁၄
၂၇။		နမ့်ဖတ်ကာ	၂၀၁၃ နိုဝင်ဘာ ၁၄	၄၉	၂	၅၁
၂၈။		ကျောက်မဲ	၂၀၀၃ ဒီဇင်ဘာ ၁၈	၁၅၄	၁	၁၅၅
၂၉။		တာမိုးညး	၂၀၁၄ ဇွန်လ ၁	၃၉	၂	၄၁
၃၀။		နမ့်တူ	၂၀၁၄ အောက်တိုဘာ ၅	၈၁	၀	၈၁
၃၁။		နမ့်ပေါင်	၂၀၁၄ ဇူလိုင် ၁	၅၃	၂	၅၅
၃၂။		တန့်ယန်း	၂၀၁၅ ဇန်နဝါရီ ၂၀	၉၆	၂	၉၈
၃၃။		နမ့်ဆန်	၂၀၁၅ ဇန်နဝါရီ ၂၀	၇	၀	၇
၃၄။		သီပေါ	၂၀၁၆ ဇူလိုင် ၁၂	၈၄	၁	၈၅
၃၅။		နောင်ချို	၂၀၁၇	၂၉	၀	၂၉
၃၆။		မိုးမိတ်	၂၀၁၇	၉၉	၀	၉၉
၃၇။	ရှမ်း(အရှေ့)	တာချီလိတ်	၂၀၁၀ ဇန်နဝါရီ ၂၅	၁၃၇	၁၀	၁၄၇
၃၈။	စစ်ကိုင်း	စစ်ကိုင်း	၂၀၁၃ နိုဝင်ဘာ ၂၄	၁၉၇	၀	၁၉၇
၃၉။		မုံရွာ	၂၀၁၃ အောက်တိုဘာ ၅	၄၁	၀	၄၁
၄၀။		ကလေး	၂၀၁၃ ဩဂုတ် ၁	၂၁၂	၂	၂၁၄
၄၁။		ကောလင်း	၂၀၁၃ နိုဝင်ဘာ ၈	၂၄၇	၁	၂၄၈
၄၂။		ပင်လည်ဘူး	၂၀၁၄ မေလ ၆	၄၀၇	၁	၄၀၈
၄၃။		ကသာ	၂၀၁၄ ဇန်နဝါရီ ၁	၁၆၉	၁	၁၇၀
၄၄။		တမူး	၂၀၁၄ ဇွန်လ ၁၀	၁၅၀	၆	၁၅၆
၄၅။		ခန္တီး	၂၀၁၄ ဇန်နဝါရီ ၂၀	၂၁၈	၅	၂၂၃


၄၆၄၇		ဟုမ်းမလင်း နောင်ပိုအောင်	၂၀၁၄ ဇွန်လ ၁၇	၃၅၇	၃	၃၆၀
၄၈။		ဗန်းမောက်	၂၀၁၄ ဩဂုတ် ၁၉	၂၀၈	၀	၂၀၈
၄၉။		ဖောင်းပြင်	၂၀၁၆ ဇွန်လ ၆	၂၂၄	၀	၂၂၄
၅၀၊ ၅၁။		အင်းတော် (မော်လူးပါဝင်)	၂၀၁၆ ဇူလိုင် ၁	၅၇၂	၃	၅၇၅
	စုစုပေါင်း			၁၃၂၄၆	၁၉၅	၁၃၄၄၁

rwcu/ / aemiya t mir vem ta& twuu [r;rvi;&v'rsm;Eiayi;í azm jyxm;yon/
armv;r vem ta& twuu vn; t i;awm&v'rsm;Eiayi;í azmjy x m;yon/

&eyai&&Eiaom taet x m; t& ruo'wuau; aom ae&m rsm; wzn;jzn;w; wursm;-
jym;vmonu at m uy;twi;awjriEiyon -




y (3) ruo'wuau; aom ae&m rsm; Ep t v u w; c v my/




y (4) 2006 r 2017 t wi; ruo 'aq;ce; t a& twu t v u
venw;wu vmy/

Methadone centers and density of Methadone patients in Myanmar 2017




y(5)jrermei i twi; ruo'wuau; aom a' o t v u vem t i t m; jyy/


wk'a'oiu'Dyne, t vkruf'kbu'bl;sm;




y (6)rEav;wi;a'oiu;wi ruo';aomuo;or;u
ae&m t v uaw&y/



y (7) uciyne, twi;&ruo';aomuo;or;u
ae&m t v u aw&y/



y (8) &r;ijne , twi;&ruo';aomuo;orm;u ae&m t vuaw&y/



y (9) ppui;wi;a'ou; twi;&ruo';aomuo;orm;u ae&m t vuaw&y/




&r;jynajrmuyi; aemicllrwi ruo';aq;ce;zi vp&e
t oay;aq;aE;wiiyp0/



oe;eri& ruo';aq;ce;wi vma&muaq;aomuaeonu
awjri&p0/

3) ru6'HpD0E8wlay;ipyfkykio0eaiqiffr;
2014 cEpwi r; , paq;taumwi; x;o;o;porsm;qi&m bupvr;jclaom0eaqmirrsm;
teur tcl'u ruo';tptp0ü ayi;pyvyaqmiay;ici;zi eiiawm\ tycs tiAiyó emu
wejyeaj&i;&mwi yr taxmu tuizpap&eaqmi&ucy,on/ 2014 cEpwi jy/vycaom
Integrated Biological and Behavioral Surveillance t & av vmrjy/vycon ae&m&
r; , paq;x; o;porsm; t lum; tycs tiAizpym;ru at muytwi; awjriEiy,on/

Figure 57. HIV prevalence among male PWID respondents - IBBS and HSS results



Denominator: All male respondents

y (10) r; , paq;x;o;por_{sm}; t lu_m; tycs t iA_r& ao;ppaq;ici;? at t mw;zi uoay;ici;?

ay;i;pyvyaqm iaom vyie;r_{sm};wi tycs t iA_r& ao;ppaq;ici;? at t mw;zi uoay;ici;?
r; , paq;x;o;por_{sm};ei ai;w\ viquqzurs_{sm}; twu ue';jzea0ay;ici;? ynmay; vu
ur;pmapnir_{sm};jzea0ay;ici;? t oa&mi b u;puc&ci; & r& ppaq;ici;Ei t oa&mi by;
um u , aq;x;ay;ici;? t oa&mi p & r& ppaq;ici;? wba&m*ppaq;u o;ici;? um v o;m; a&m*
r_{sm}; ppaq;u o;ici;w y0iy;on/

Z , m; (11) ay;i;pyvyaqm iaom vyie;r_{sm};wi tycs t iA_r& ao;ppaq;ici;? at t mw;zi uoay;ici;?

t ñe;ue;r _{sm} ; t vu aqm u&ucurs _{sm} ; ⁹	u _{sm} ;	r	ppay;i;
tycs t iA _r & r& ppaq;iy; & v'u vn; o&aom ruo'; aomuo;or _{sm} ; ta&twu	5298	96	5394
tycs t iA _r & r& ppaq;iy; & v'u vn; o&aom ruo'; aomuo;or _{sm} ; \ viquqzurs _{sm} ; ta&twu	8	72	80
t oa&mi b & r& ppaq;aom ruo';vem ta&twu	4562	73	4635
t oa&mi b y;um u , aq;u ovrwc;u twi; x;Eaom ruo';aomuo;on vem ta&twu	1368	17	1385
t oa&mi p & r& ppaq;aom ruo';aomuo;ao vem ta&twu	4178	48	4226

t jcm;aom vyie;aqmi&ucsu &v'rsm;	
r; , paq;x;o;porsm; t m; ay;a0aom ynmay;v uur;pmapmi ta&twu	22725
r; , paq;x;o;porsm; t m; ay;a0aom ue'; ta&twu	124160
at t mwuorc , &e vajymi;ay;con r; , paq;x;o;poayi;	656
umvom;a&m*juorc , &e vajymi;ay;con r; , paq;x;o;poayi;	105
wba&m*juorc , &e vajymi;ay;con r; , paq;x;o;poayi;	249
jzeaoaom r; , paq;0; t E&m , ynmay;pmapmi ta&twu	3089
ynmay;a [majymcaom au;mi;om;^ausmi;o ta&twu	1218



aemicll ru o 'aq;ce;wi ao;ppaq;&e twu ao;eremazmu
, aey



&r;jynajrmuyi; we , e;lrwi r; , paq;0; t E&m , t oynmay;
a [majymaey

4) t p n f t a 0; E s v j k d e y c i

- t r s l ; o m ; r ; , p a q ; 0 ; x e ; c y a & ; r 0 ; ' a & ; q j c i ; /
(u) t r s l ; o m ; u i r ; u s i o r s m ; t p t z E i o ; o y a q ; a E ; j c i ; (2017 Zev 6'7)/
(c) t r s l ; o m ; r ; , p a q ; 0 ; x e ; c y a & ; r 0 ; ' t w n j y a & ; q i & m a q ; a E ; y (2017 E o i b m 2017)/
- v x t a i c j y a q ; u o a & ; t w u u a v ; l r i w i t o a y ; a q ; a E ; j c i ; (2017 'Z i b m 16)/
- u a v ; l r i w i l r l e , t E & m , a v m c a & ; a u m r w t p n ; t a 0 ; w i y 0 i w u a & m u j c i ; (2017 'Z i b m 16)/
- r ; , p a q ; o ; p o r s m ; q i & m v y i e ; t z t p n ; t a 0 ; (2017 l o * w 8 ' a t m u w b m 30)/
- r u o ' ; v r ; ñ e j y e v n o ; o y j c i ; q i & m t v y ½ a q ; a E ; y (2017 p u w i b m 22)/
- u v b p r u e ; \ t j y n j y n q i & m a q ; p u o a & ; o i ½ ; ñ e ; w r ; b m o m j y e u u i r ; u s i o r s m ; u j y e v e o ; o y j c i ; q i & m t p n ; t a 0 ; (2017 { y v 25-27)/



u a v ; l r i w i l r l e , p r u e ; 0 ; a q m i a u m r w t p n ; t a 0 ; u s i ; y p 0



u v b p r u e ; o i ½ ; ñ e ; w r ; b m o m y e u j y n w i ; u i r ; u s i o r s m ; j z i
o ; o y a q ; a E ; & m ü y 0 i o r s m ; u a w & y

5) p a q m i f n f r w i a y ; c i f

2017 cepwi 2012 u j y p x m ; a o m r u o ' ; u o j c i ; E i r ; , p a q ; p u o j c i ; v r ; ñ e u j y e v n
o ; o y y ; j y i q i z n p u & e a q m i & u c y o n / ð i ; w u a t m u y ; t w i ; a z m j x m ; y o n -

(1) r u o ' ; t p m ; x ; u o j c i ; e i a q ; p u o j c i ; q i & m v r ; ñ e (j y i q i z n p u j c i ;) /

(2) r u o ' ; t p m ; x ; u o j c i ; q i & m v y i e ; p c e p ñ e ; r s m ; (2 0 1 7 a t m u w b m)

(3) j r e r m e i i w i p w u a q ; o ; p r u o j c i ; q i & m v r ; ñ e (2 0 1 7 e o i b m)

r ; , p a q ; p u o a & ; E i o a w o e x m e t a e j z i j y i v y c a o m o i w e ; r s m ; (Z , m ; 1 2) r m a t m u y ;
t w i ; j z p y o n -

p0	t a l u m i ; t & m	a e & m	& u p	0 ; a &
1/	r ; , p a q ; o ; p r u m u , a & ; E i	r E a v ;	2017 azazm0;& (15-19)	49
2/	r u o ' ; t p m ; x ; u o e n ;	j r p l u ; e m ;	2017 ar v (22-24)	45
3/	o i w e ;	v m ; ½ ;	2017 puwi b m (11-13)	55
4/	r u o ' ; t p m ; x ;	r E a v ;	2017 azazm0;& (20-21)	55
5/	u o r q i & m E p o r a q ; a E ; j c i ;	j r p l u ; e m ;	2017 ar v (25-27)	47
6/	o i w e ;	v m ; ½ ;	2017 puwi b m (14-16)	52

7/	r ; , paq;o;pr umu , a&ei ruo' ; tpm; x; uo;ci;qi&m aq;aE;o ilum;ci;	lrw	2017 lo*w (24-25)	32
8/	v x t a;cy/aq; uo;ci;Ei aq;puo;ci;qi&maq;aE;y	b m; t	2017 lo*w (29-30)	31



r ; , paq;puo;ci;Eiru o' ;oiwe;u jrpl;u;em;ü zi vpp0
uc;i;yne , 0eju;c;lyu tzi trmpum;ajm lum;aey



v x t a;cy/aq;puo;ci;ty;t0i r ; , paq;puo;ci;oiwe;u
bm; tlrwi usi;yp0



r ; , paq;o;porsm; t m; jynov x t aicyu o jci; q i& m q iym; o iwe;wi
r ; , paq;0;wm;q;ErEi;a&;&wyzrl;u t rmpu m;ajm l u m;aey

6)okwoeqi fCuf;

2017 cEp t wi;aq mi&ucaom oawoeEiav vm qe;prrsm;rm a t m uy t wi;jzpy;on/

1. Way forward for Methadone Maintenance Treatment (MMT) Program: Looking at a glance at a high burden area (Nanda Myo Aung Wan, Kyaw Lwin Show, Yin Thet Nu Oo, Le Le Win, Kyaw Thu Hein; DDTRU and Department of Medical Research)
2. Analysis of Methadone programme data, client profile, treatment outcomes, referrals and linkages to antiretroviral treatment and TB care among drug users in Myanmar – generating Myanmar-specific evidence on retention in treatment and referral to care (DDTRU and WHO)
3. Mapping of Substance Abuse Treatment and Care Facilities (DDTRU and UNODC)

ouq&tz&pnfr&E&ayia&mi&it&Q&if

- uvor* tzt pn; rsm; / / urm use; ma& tz (WHO) uvor* r; , paq; 0; ei jyp rqi&m; 2; (UNODC) uvor* tycs tiA^at ti' tupqi&m ñeay; i; tz (UN-AIDS) uvor* prc&u vyie; rsm; qi&m tz (UNOPS)
- r; , paq; 0; qi&m tE&m , avsm&usa& vyie; vyaqmi&aeaom jynwi; ^jyny tp& r [waom tzt pn; rsm; / / rerm&ei ir; , paq; 0; qe&usia& t oi; (Myanmar Anti-Narcotics Association –MANA) ? Asian Harm Reduction Network (AHRN), Burnet Institute (BI), Health Poverty Action (HPA), Medicine du Monde (MDM), papwwaom aq; 0; rsm; qi&m oawo&etz (Substance Abuse Research Association – SARA)

r; , paq; puo&Ei oawoe&Xmer prc&ureae*sm tae&zi r; , paq; 0; por&sm; qi&m vyie; tz (Drug User Working Group – DUWG) \ Ou| t jzpv n; y; ay; i; vyaqmi vsu&y on/ t qy; vyie; tzon r; , pA [tz uvor* tzt pn; rsm; (UNODC, UN-AIDS, WHO) ei tE&m , avsm&usa& vyie; vyaqmi&aeaom tp&r [waom tzt rsm; ru , pm; v , rsm; jizi zpn; xm; yon/ t qy; vyie; tz on tycs tiA^at ti' tup en; ynm yi; qi&m r [nAsL [m tzt wu tlu&UmPrsm; ay; &e ta&yao&mtzvn; jzpouo atmu ajcwi tE&m , avsm&usa& vyie; rsm; taumi t xnazmaerEi ywou í ay; i; pynEi; rrrsm; aqmi&u&mwi ta&yao&mtzvn; jzpyon/

tE&m , avsm&usa& vyie; rsm; taumi t xnazmaqmi&uaeon tp&r [waom tzt pn; rsm; on atmu&ajc t qiwi ruo' ; tpm; x; uo& vyie; rsm; at mi jripm aqmi&uEi ap&e t wu Xmeqi&mO&exr; rsm; ei twy; ay; i; í vuvvyaqmi vsu &y on/



uvbprue;\ r; , paq;puojci;q i&m oiwe;ziywi r; , pA[r
tzi t rmpum;ajymum;ae y



r; , paq;puoa&;Eijyevn xaxmia&;qi&m t vy¼aq;aE; ywi r; , pA[r
tzi t rmpum;ajymum;ae y

r; , paq;0; o;pr jy ó em on eiiawmz lz;w;wua&; twu t;u;rm;aom lcr;ajcm urwpc
vn; jzpaeyon/ eiiawm\l r0; 'rsm; w;wuajym i; vvm on Ei t r l r; , paq;p uoa&;ei
oawoeXme taejz i vn; jynov x t ajcy l aq;puoa&; vyie;rsm; vyaqmieia&; twu
uvor* r; , paq;0; Ei jyp rqi & m 1/2; Ei tw 2017 cepwi 0; aqmi vy& m; cy; ? j rerm Ei i \
r; , paq;0; x e; c; i ya&; q i & m r 0; 'a&; q & m w i vn; r; , pA [Ei tw t w w u v u w a q m i
& ucyon/ r; , paq;puoa&;ei oawoeXmetaejz i ruo'; t p m; x; uoa&; vyie;rsm;
u vn; 2017 cepü r; , paq;o;pr rsm;aom ae& m (5) ae& m w i vyie;rsm; w; c; c; c i; t m; j z i v
em rsm; taejz i 0eaqmi r rsm; u yrv , viwu&& t m i aqmi & uay; cyon/

aq;o;pr yprsm; ajym i; vaejci; ? r; , paq;0; \ q; u s; rsm; u em; vnoabmayur t m; en;
jci; ? v i , v & , rsm; taejz i t o p t qe; u pr; oypepm; vjci; pon t ajc taersm; on vn;
t & i; tjrprsm; t uetowjz i vyaqmiea& on aq;puoa&; u @ twu peacryi jzpy
on/ yre t m; j z i ruo'; aom uon vemrsm; on aq;wuaomXmeo aep0vma& m i faq;
aom uae& on jzp& m aq;wuay; & aom 0exr; rsm; twu w; ym; vmaeaom vem0; a& ei tw
aep0vemay; i; rsm; pm u wuau; ay; ae& on r m vn; vyie; cipeacrwpcoz , jzpaeyon/
2017 cepwi & eueEirEav; ü t v t av sm u aq; ciew , Eiaompu epv; u wyqia y; c
ojz i xae& m rsm; wi ruo'; wuau; ; & m ü y r t q i a jcyon/ t v m; wyi t jcm; aom ruo';
aq; ce; rsm; w i vn; aemiwix o t v t av sm u ciew , aompur sm; wyq i v m Eiyu aq;
wuay; & aom 0exr; rsm; taejz i vyie; yrw ius , vmrn jzpyon/ rnoyi jzpapur
r; , paq;p uoa&; Ei oawoeXme taejz i t m; v; Ei y; ay; i; aqmi & u jci; jz i vyie;rsm; u
& nre; x m; on twi; jynr& e i u l; yr; aqmi & u v s u & yon/

aem uquw (1) use; rma&Ei t m; upm; 0e! u; Xmer xwiyecaom t realumjimpmrsm; t u; 0;

t realumjimp	t alumi; t &m
1^2002	1988 cEp ueAi;&i; t & xe;c!y"mwypn;rsm; t jzp ovrwon "mw aA'ypn;rsm; pm&i;
2^2002	1971 ueAi;&i; t & pwuajymi; vapao m aq; 0;rsm; Z , m; (1)? Z , m; (2)? Z , m; (3)? Z , m; (4)? Z , m; (5)/
3^2002	1961 cEp wpcwn;aom ueAi;&i; t & r; , paq; 0;rsm; Z , m; (1)? Z , m; (2)? Z , m; (3)/
4^2002	aq; pu oa&Xme! u;rsm; ovrwalumjijci;/
5^2002	aq; pu oa&Xmi , rsm; ovrwalumjijci;
1^2004	1971 ueAi;&i; t & Amineptine u pwuajymi; vapao m aq; 0;rsm; Z , m; (2) wi x noi;jci;/
1^2005	1971 ueAi;&i; t & Zolpidem Ei Ketamine u pwuajymi; vapao m aq; 0;rsm; Z , m; (4) wi x noi;jci;/
2^2005	1961 cEp wpcwn;aom ueAi;&i; t & be;pm yi Mytragyna Speciosa Ei Tramadol u r; , paq; 0; Z , m; (3) wi x noi;jci;/
6^2010	1988 cEp ueAi;&i; t & Safrole rich oil u xe;c!y"mwypn;rsm; Z , m; (1) wi x noi;jci;/
10^2012	Mytragyna Speciosa (Kratom) t av;c!e ovrwici;/ be;pm&u t ajcnu (o) be;pm rejzpyu t av;c!e 1 'or 5 u v*&rEi t x u u v n;aumi; be;pm&u t pizpyu t av;c!e 6 u v*&rEi t x u u v n;aumi; v u 0 , x m;&jci;/ o , , yaqmijci; wpqia y;jci; vajymi; ay;jci; jiyu a&mi;c&e t v im [ovrwici;/

aem uquw (2) r; , paq; o; por sm; qi& mvyie; t z\ zpn; yEi vyie; w mOer sm; /

w mOe	0e! u; Xme^ Xme^ t z t p n;
0u	prc: ureae* sm? r; , paq; pu oa& ; Ei oawoe! aq; u oa& ; O; p; Xme? use; rma& ; 0e! u; X m/
wzu0u	r; , pA [r u , p m; v , wp0; ? jyn xa& ; 0e! u; Xme
t wi; a& ; r l;	aq; pu oa& ; Xme! u; r sm; o wrwa l u m j i m j c i; /
t z0 i r sm;	t r s l; o m; ccu: ^ u m v o m; wuz: ua& ; Xme (jyn o use; rma& ; O; p; Xme)? vr0 ex r; Xme? UNAIDS, WHO, AHRN, BI, National Drug Network Myanmar (NDNM), AIDS Alliance, HPA, Save the Children - PR, UNOPS - PR, 3MDG, Drug Policy Advocacy Group (DPAG), PSI, apm rev rz l z; a& ; t o i; /

vyie; w mOer sm;

- 1/ tycs t iA^ at t i' t upqi& m t r s l; o m; r [mAsL [m? vyie; t p t p0? & eyaiwuc: u jci; ponwtwuEi r; , paq; O; j y ó emEi ywou í Oya' ? r0? ' qi& m en; ynmyi; t luÚ mPr sm; ay; & e/
- 2/ en; ynmqi& m r [mAsL [m tzo v tyao m t luÚ mP taxmu ty r sm; ay; & e? Oyr m t m; jzi -
(u) vr; ñers m; j y p j c i; ? j y i q i z n p u j c i; wu unyy; ay; & e/
(c) t E& m , av sm u sa& ; vyie; r sm; w; csaqmi& u& e/
- 3/ r; , paq; o; z; or sm; \ ue& u r sm; cirm t m; aumi; vmap& eEi t jcm; aom rwzurs m; Ei cswqu vyuiEi& e unay; jci; /
- 4/ t jcm; aom tycs t iA? at t i' t upqi& m t v m; w vyie; t z r sm; jzpaom j y p a p m i a& m urqi& m t z? a& a j y m i; o m; v m o r sm; q i& m t z? v i , r sm; q i& m t z? rciruav; o u; purumu , a& ; t z? rbrEi t m; en; cswaom uav; r sm; q i& m t z? v i v y o m; r sm; q i& m t z p o n t z r sm; E i n E i; a q m i& u& e/
- 5/ t "u t ñe; ue; r sm; ? vr; j c r q i& m a e m u q; & a o m t c u t v u r sm; & & e i& e a q m i& u j c i; j z i v u& taumit x naz m& mwi u m [c u r sm; o& e i a p& e? a q m i& u q vyie; r sm; yr t m; aumi; vmap& e? r; , paq; o; pralumi tycs t iA j y ó em r sm; av sm u s o m; a p& e? vyie; a q m i& u c u r sm; \ & v ' E i t u s l; o u a& m u r r sm; w; w u aumi; reap& e/

- 6/ Operational research, denominator population exercise, behavioral studies pon oawoer_{sm}; a&q taumi t x nazmji;/
- 7/ r0'i ei vyie; taumi t x nazmrqi&mr_{sm};? tE&m , av_{sm} usa&q i&m r0'i alu mji m
cs ur_{sm}; u t oay; aq; aE; ci; vyie; r_{sm}; azma qmi ay; ci;/

¹Uvor; , paq;0;Eijyprqi&m½; \ 2016^2017 cep urmr; , paq;0; t p&icpmrsm;/

²Jrmeriir; , paq;0;xe;cly&Epywv n t p&icpm (2016 cep) r; , pA [t z/

³Report of the HIV Sentinel Sero-surveillance Survey, 2008: NAP, DoH Myanmar

⁴Technical Guide for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users; WHO, UNODC, UNAIDS

⁵National Guidelines: A Core Package for HIV Prevention amongst Key Populations in Myanmar, October 2014: NAP, DoH, Ministry of Health

⁶t reajumjimp t rw 3^2016 r; , pA [t z/

⁷The 2014 Myanmar Population and Housing Census: Thematic Report on Children and Youth, Census report volume 4-M, Department of Population, Ministry of labor, Immigration and Population, Myanmar.

⁸Myanmar Integrated Biological and Behavioral Surveillance Survey and Population Size Estimates among People Who Inject Drugs 2014, Ministry of Health and Sports Myanmar

⁹National Strategic Plan on HIV and AIDS Myanmar (2016-2020)

Table of Contents

Abbreviations

Introduction

Policy context	1
Objectives	3
	7

Activities (2017)

1. Drug Treatment services	9
2. Methadone Maintenance Therapy	9
3. Integrated services of MMT	16
4. Meeting and Workshops	23
5. Capacity Development	27
6. Research activities	28
Collaboration with stakeholders	30
	31

Conclusion

33

Annexes

Annex 1: Summary of Notifications issued by Ministry of Health & Sports	34
Annex 2: Drug User Working Group structure and functions	35

Figures

Figure 1: Youth and other age groups among new admissions in 2017	12
Figure 2: Heroin, Opium and ATS use among 2017 admissions	13
Figure 3: Expansion of MMT sites by year	19
Figure 4: MMT clients (Daily active) against MMT sites (2006 – 2017)	19
Figure 5: Figure 5: Current methadone maintenance treatment sites in Myanmar by Region/States with caseload	20
Figure 6: Methadone patients in Mandalay Region	21
Figure 7: Methadone patients in Kachin State	21
Figure 8: Methadone patients in Shan State	22
Figure 9: Methadone patients in Sagaing Region	22
Figure 10: HIV prevalence among male PWID respondents	24

Tables

Table 1: Structure of Drug Treatment sector	4
Table 2: Major DTC, minor DTC and MMT sites	9
Table 3: New admissions by gender	11
Table 4: New admissions by age groups	11
Table 5: New admissions by types of drugs used	13
Table 6: New admissions by method of using drugs	14
Table 7: New admissions by education	14
Table 8: New admissions by occupation	15
Table 9: Total admissions in 2017	16
Table 10: Methadone patients in 2017	17
Table 11: Achievements of integrated services	25
Table 12: Training sessions organized by DDTRU	28
References	



Abbreviations

AHRN	Asian Harm Reduction Network
AIDS	Acquired Immunodeficiency Syndrome
ATS	Amphetamine Type Stimulants
BI	Burnet Institute
DDTRU	Drug Dependency Treatment & Research Unit
DTC	Drug Treatment Center
CCDAC	Central Committee for Drug Abuse Control
DoH	Department of Health
DUWG	Drug User Working Group
HIV	Human Immunodeficiency Virus
HPA	Health Poverty Action
ICCE	International Centre for Credentialing and Education of Addiction Professionals
MANA	Myanmar Anti-narcotic Association
MDM	Médecins du Monde
MMT	Methadone Maintenance Therapy
NAP	National AIDS Programme
PSI	Population Services International
PWID	People Who Inject Drugs
SARA	Substance Abuse Research Association
SDG	Sustainable Development Goal
UN	United Nations
UNODC	United Nations Office on Drugs & Crime
UNAIDS	Joint United Nations Programme on HIV/AIDS
UNOPS	United Nations Office on Project Services
WHO	World Health Organization

Introduction

Use of illicit drugs was an expanding problem worldwide and causing health, social and economic consequences of people in many countries affecting development. According to UNODC reports, there were estimated 247 millions of people who use drugs as per 2016 report and 255 million as per 2017 report. Estimated numbers of people with drug use disorders were 28.7 million in 2016 report and 29.5 million in 2017 World Drug Report of UNODC¹.

In Myanmar, increased seizures of illicit drugs also reflects increasing drug abuse problem in the country. According to 2016 report of CCDAC, there were 769.26 kilograms of heroin (186.04 Kilo in 2015) and over 98.35 million of stimulant tablets in 2016 (over 49.5 million in 2015)² were seized and reflected increased illicit drug activity.

DDTRU was established since 1976 and its activities were increased gradually along with the changes in the field of drug use. Initially, DDTRU mainly worked for drug treatment activities and later, public health problems appeared as a consequence of injecting drug use. Prevalence of HIV became a significant threat to the country and prevalence was also high among people who inject drugs (PWIDs). According HIV sero-sentinel surveillance report of National AIDS Program (NAP) in 2008, HIV prevalence among PWIDs was 37.5% which was the highest among other risk groups. In that report, HIV prevalence among PWIDs across sentinel sites were 37.4% in Lashio, 37% in Mandalay, 54.5% in Myitkyina and 43.3% in Muse³. To respond the situation, harm reduction programs were implemented in areas where drug use was prevalent. Due to the use of heroin as a main drug for injecting drug use in Myanmar, DDTRU also started piloting of methadone replacement therapy as an opioid substitution therapy with the support of WHO at four sites (Yangon, Mandalay, Lashio and Myitkyina) in 2006.

In addition to HIV problem, blood borne transmission of hepatitis viruses also became a threat to communities and also caused public health threat to PWIDs as well. Therefore, DDTRU also included rapid testing and vaccination for hepatitis B in its activities.

In 2009, UN agencies⁴ announced comprehensive package of services for PWIDs and National AIDS Program of Department of health in Myanmar also issued 'National Guidelines: A core package for HIV prevention amongst key populations in Myanmar' in 2014⁵. Comprehensive package for PWIDs included nine interventions and NAP also prescribed same package of services for PWIDs. The package included opioid substitution therapy and other evidence informed drug treatment, and hepatitis care covering prevention, vaccination, diagnosis and treatment of hepatitis.

At the time of this reporting period, there were 26 major drug treatment centers, 47 minor drug treatment centers and 51 methadone dispensing sites across the country. Methadone program was working in partnership with UN agencies, NAP, local non-government organizations and international non-government organizations.

Policy context

As drug use becomes global problem, world leaders also included substance abuse problem in Sustainable Development Goals (SDGs) 2030 agenda. SDG (3) was adopted as "Ensure healthy lives and promote well – being for all at all ages". Under SDG (3), the goal 3.5 was "Strengthen the prevention and treatment of substance abuse, including narcotic drug abuse and harmful use of alcohol" and among indicators, indicator 3.5.1 was mentioned as "Coverage of treatment interventions (pharmacological, psychosocial and rehabilitation and aftercare services) for substance use disorders".

Being a signatory to UN drug conventions, Myanmar enacted Narcotic Drugs and Psychotropic Substances Law (1993) which was under revision at the moment. Myanmar also formulated National Drug Control Policy in 2017 and DDTRU also involved all along the process. According to the policy, approach to drug problem would be health oriented approach and included four policy areas;

- Supply Reduction and Alternative Development
- Demand reduction and Harm reduction
- International Cooperation
- Research and Analysis

In line with 1993 law, CCDAC (Central Committee for Drug Abuse Control) formed committees according to respective sectors and drug treatment sector was formed as below⁶;

Table 1. Structure of Drug Treatment Committee

No.	Representatives	Ministry/Department	Designation
1.	Permanent Secretary	Ministry of Health and Sports	Chairperson
2.	Deputy Director General	General Administration Department, Ministry of Home Affairs	Member
3.	Deputy Director General (Disease Control)	Department of Public Health	Member
4.	Deputy Director General	Department of Medical Services	Member
5.	Deputy Director General	Social Welfare Department, Ministry of Social Welfare, Relief and Resettlement	Member
6.	Director (Head of Department)	Planning Department, Drug Enforcement Division	Member
7.	Consultant/Addiction Professional assigned by Chairperson	Department of Medical Services	Member
8.	In-charge / Project Manager	Drug Dependency Treatment and Research Unit	Member
9.	Director General	Department of Medical Services	Secretary

According to notification 3/2016 of CCDAC, the duties of drug treatment sector were as follows;

1. Adopting policy, goals and objectives in order to perform drug treatment measures effectively and successfully.
2. Conducting assessments and surveys such as epidemiology of drug use disorders, population size estimation for people who use drugs, integrated biological and behavioral surveys, household surveys and school surveys etc.
3. Setting up a surveillance system on the use of narcotic drugs and psychotropic substance and its consequences.
4. Formulating and implementing plans on prevention, treatment and harm reduction activities based on findings.
5. Coordinate and collaborate with relevant departments, UN organizations, and non-governmental organizations in order to obtain necessary supports while implementing drug treatment measures.
6. Continuous learning of new therapies on emerging new psychoactive substances in addition to opium, heroin and stimulants, providing treatments accordingly and conducting research on treatment outcomes.
7. Capacity building of drug treatment professionals and create new generation of medical professionals.
8. Expanding and upgrading drug treatment centers for wider accessibility of those with drug use disorders.
9. Developing guidelines, organizing training sessions, coordinating with relevant departments for community based drug treatment and conducting measures of implementation.
10. Formulating policy to reduce harmful consequences of drug use and implement activities.
11. Conducting awareness raising activities on risks and harms of drug use in collaboration with relevant departments.

12. Coordination with relevant departments for rehabilitation of people who use drugs after completion of drug treatment.
13. Managing with respective head of departments of medical services in Region, State, Naypyitaw Union Territory to provide close supervision and fulfilling requests submitted to them in order to implement drug treatment activities successfully.
14. Submission of progress reports to central committee occasionally.
15. Monitoring and evaluation of implementation of drug treatment measures.
16. Management and supervision of budget expenditures on drug treatment activities and managing in accordance with needs if budget contribution is from allocation of Region/State government budget.

Objectives

DDTRU revised its objectives in 2017 in line with changing situations and activities.

1. To improve quality of integrated, innovative and voluntary-based comprehensive drug treatment services
2. To promote continuity of care to improve the response to the chronic and relapsing nature of drug dependency
3. To promote and support development of community-based comprehensive drug treatment response
4. To strengthen coordination, collaboration and capacity building to improve drug treatment service response
5. To strengthen and share cross cutting strategic information and research of evidence-based practices to improve comprehensive drug treatment response



Vice President visiting booth show on International Day against Drug Abuse & Illicit Trafficking



Union Minister of Health & Sports visiting booth show



The 38th meeting of Asean Senior Officials on drug matters in Vietnam

Activities (2017)

1. Drug treatment services

Major drug treatment centers, minor drug treatment centers and methadone dispensing sites could be seen as below;

Table 2. Major DTC, minor DTC and MMT sites

No.	State/ Region	Major DTC	Minor DTCs	MMT Sites
1.	Yangon	Yangon	-	Yangon (2)
2.	Mandalay	Mandalay	Pyinoolwin, Mogoke Pyinmana, Myingyan (4)	Mandalay Pyinoolwin Mogoke (4)
3.		Meiktilar		
4.		Kyaukse		
5.	Sagaing	Monywa	Homalin, Tigyaing, Hkamti, Kanbalu, Indaw, Katha, Wuntho, Kyunhla, Pinlebu, Banmauk, Kawlin, Tamu, Shwebo, Mawlaik (14)	Sagaing, Monywa, Kale, Tamu, Kawlin, Pinlebu, Katha, Banmauk, Indaw, Mawlu, Homalin, Naungpoaung, Hkamti, Paungbyin (14)
6.		Kalay		
7.	Kachin	Myitkyina	Mogaung, Mohnyin, Hpakan, Waingmaw, Momaug, Puta-O (6)	Myitkyina, Aung- myintha, Bhamo, Waingmaw, Mogaung, Namte, Hopin, Mohnyin, Chipwi, Hpakan + Seikmu, Lonekhin, Mansi, Shwegu, Momaug (15)
8.		Bhamo		
9.	Shan (East)	Kengtung	Monghsat, Mongyang, Mongyawng, Monghpyak, Tachileik (5)	Tachileik (1)

10.	Shan (North)	Lashio	Kunlong, Kutkai, Kyuakme, Laukkaing, Manton, Monekoe, Mongmit, Muse, Namhsan, Nanhkan, Pangsang (11)	Lashio, Hseni, Kutkai, Namphatka, Muse, Nanhkan Kyaukme, Tamoe-nye, Namtu, Nam-paung, Tangyan, Namhsan, Hsipaw, Nawngkhio, Mongmit (15)
11.	Shan (South)	Taunggyi	Kalaw, Kunhing, Mongshu, Nansang (4)	-
12.		Loilen		
13.	Ayeyarwady	Pathein	-	-
14.		Hinthada		
15.	Bago	Bago	Thayarwady (1)	-
16.		Pyay		
17.		Taungoo		
18.	Chin	Hakha	-	-
19.	Kayin	Hpa-An	Myawaddy (1)	-
20.	Kayah	Loikaw	-	
21.	Magway	Magway	-	-
22.		Pakokku		
23.	Mon	Mawlamyine	-	-
24.	Rakhine	Sittwe	-	-
25.	Tanintharyi	Dawei	Kawthoung (1)	-
26.		Myeik		
	Total	26	47	51

Drug treatment services were also available in two youth rehabilitation centers (Shwe Pyi Thar and Shwe Pyi Aye), 49 border area hospitals and township hospitals across the country.

Drug treatment in 2017

New admissions by gender (Table 3)


	Yangon	Mandalay	Sagaing	Kachin	Shan (E)	Shan (S)	Shan (N)	Bago	Mon	Kayin	Tanintharyi	Total	%
Male	929	891	1428	2469	239	102	656	129	72	104	412	7431	98.61
Female	29	2	8	35	16	1	13	0	0	0	1	105	1.39
Total	958	893	1436	2504	255	103	669	129	72	104	413	7536	100.00

New admissions by age groups (Table 4)

	Yangon	Mandalay	Sagaing	Kachin	Shan (E)	Shan (S)	Shan (N)	Bago	Mon	Kayin	Tanintharyi	Total	%
10- 14	3	2	0	1	0	0	3	0	0	0	0	9	0.12
15-19	92	77	34	83	15	3	16	16	22	12	32	402	5.34
20-24	278	254	202	559	41	22	86	42	21	25	82	1612	21.41
25-29	235	201	275	549	30	24	112	44	10	20	107	1607	21.34
30-39	267	231	591	868	79	29	231	21	15	36	128	2496	33.15
40-49	76	95	264	349	51	15	140	5	4	8	61	1068	14.19
50-59	7	30	66	100	35	10	71	1	0	3	7	330	4.38
60 above	0	3	4	9	4	0	10	0	0	0	0	30	0.40
Total	958	893	1436	2497	255	103	669	129	72	104	413	7529	100.00

According to 2014 population census, children (0-14 years) constituted 14.4 million (29% of total population) and youths (15-24 years) constituted 9 millions (18% of total population) and projections showed to decline in future⁷. As youths were valuable for the future of country, drug use phenomena among youths among those who received drug treatment could also be seen as below;

Figure 1: Youth and other age groups among new admissions in 2017



It could be seen that youths (15 – 24 years) came to receive drug treatment was 27.97% of total new admissions in 2017.

New admissions by types of drugs used (Table 5)

	Yangon	Mandalay	Sagaing	Kachin	Shan (E)	Shan (S)	Shan (N)	Bago	Mon	Kayin	Tanin-tharyi	Total	%
Heroin	359	855	1374	2487	106	19	644	51	19	17	5	5936	78.77
Opium	30	20	61	16	84	75	20	4	6	0	3	319	4.23
Marijuana	21	1	0	0	0	0	0	1	0	0	0	23	0.31
Tranquilizer	0	0	0	0	0	0	0	3	0	0	0	3	0.04
Amphetamine	538	17	1	0	64	9	5	70	46	87	146	983	13.04
Others	10	0	0	1	1	0	0	0	1	0	259	272	3.61
Total	958	893	1436	2504	255	103	669	129	72	104	413	7536	100.00

Among new admissions of 2017, opium, heroin and amphetamine uses could be seen as below;




Figure 2: Heroin, Opium and ATS use among 2017 admissions

It could be found that higher number of patients were admitted for treatment for heroin in Kachin, Sagaing, Shan and Mandalay Regions and those who were admitted for ATS use was highest in Yangon Region.

New admissions by method of using drugs (Table 6)

	Yangon	Mandalay	Sagaing	Kachin	Shan (E)	Shan (S)	Shan (N)	Bago	Mon	Kayin	Tanin-tharyi	Total	%
Oral	23	12	30	9	21	43	8	1	8	0	262	417	5.53
Smoking	686	168	177	225	165	50	237	88	60	75	138	2069	27.45
Injection	246	711	1229	2269	69	10	415	40	4	29	1	5023	66.65
Sniffing	0	2	0	0	0	0	9	0	0	0	0	11	0.15
Other	3	0	0	1	0	0	0	0	0	0	12	16	0.21
Total	958	893	1436	2504	255	103	669	129	72	104	413	7536	100.00

New admissions by education (Table 7)

	Yangon	Mandalay	Sagaing	Kachin	Shan (E)	Shan (S)	Shan (N)	Bago	Mon	Kayin	Tanin-tharyi	Total	%
Illiterate	4	7	8	20	85	85	49	0	0	4	18	195	2.59
Monastic	2	5	16	18	6	6	14	2	1	2	46	143	1.90
Primary	40	141	574	736	58	58	227	42	28	29	126	2006	26.62
Middle	211	299	509	907	55	55	216	50	28	37	144	2473	32.82
High	475	285	278	643	43	43	127	35	11	26	72	2026	26.88
University	148	104	40	110	4	4	19	0	4	6	1	444	5.89
Graduated	77	51	11	22	3	3	15	0	0	0	6	196	2.60
Others	1	1	0	48	1	1	2	0	0	0	0	53	0.70
Total	958	893	1436	2504	255	255	669	129	72	104	413	7536	100.00

Among new admissions, higher number of drug use was found among those with high school level (26.88%), middle school level (32.82%) and primary level education (26.62%).

New admissions by occupation (Table 8)

	Yangon	Mandalay	Sagaing	Kachin	Shan (E)	Shan (S)	Shan (N)	Bago	Mon	Kayin	Tanintharyi	Total	%
Farmer	41	110	341	682	85	40	167	5	13	16	47	1547	20.53
Sellers	85	110	87	134	41	14	24	11	2	8	4	520	6.90
Gov. Intellectual	13	11	3	5	1	1	5	0	0	0	0	39	0.52
Gov. Servants	9	5	7	22	0	0	10	0	3	4	0	60	0.80
Intellectual	61	19	4	7	1	4	9	0	0	2	6	113	1.50
Manual	114	286	333	463	36	17	210	0	18	28	169	1674	22.21
Traders	61	40	38	107	5	2	15	0	2	9	101	380	5.04
Craft work	23	17	5	21	1	1	5	0	0	0	0	73	0.97
Student	67	31	6	10	3	2	4	25	2	2	1	153	2.03
Dependent	318	185	328	468	63	22	131	42	21	18	4	1600	21.23
Retired	1	0	1	6	1	0	0	0	0	0	0	9	0.12
Odd jobs	67	51	203	402	18	0	42	46	7	11	81	928	12.31
Driver	98	28	91	177	0	0	47	0	4	6	0	451	5.98
Total	958	893	1436	2504	255	103	669	129	72	104	413	7536	100.00

Total admissions in 2017 (Table 9)

Admissions	Yangon	Mandalay	Sagaing	Kachin	Shan (E)	Shan (S)	Shan (N)	Bago	Mon	Kayin	Tanin-tharyi	Total
First	958	889	1436	2504	254	103	662	129	76	104	413	7528
Second and above	465	527	0	432	1	29	164	0	1	0	0	1619
Total	1423	1416	1436	2936	255	132	826	129	77	104	413	9147

2. Methadone Maintenance Therapy (MMT)

MMT program was started in 2006 and expanded its activities gradually. In 2017, MMT dispensing sites were increased up 51 sites. Methadone maintenance therapy was crucial for PWIDs to reduce risks of transmitting HIV and other blood-borne infections as well as social consequences.

Number of clients taking methadone in 2017 could be seen as below;

Table 10. Methadone patients in 2017

No.	State/Region	MMT site	Year started	Male	Female	Total
1,2	Yangon	Yangon	2006	560	15	575
3,4	Mandalay	Mandalay	2006	1842	19	1861
5		Pyinoolwin	2013	132	3	135
6		Mogoke	2017	207	0	207
7.	Kachin	Myitkyina	2006	668	7	675
8.		Aungmyinthar	2013	42	1	43
9.		Bhamo	2007	615	3	618
10.		Waingmaw	2011	312	1	313
11.		Mogaung	2007	561	10	571
12.		Namtee	2010	301	2	303
13.		Hopin	2012	524	7	531
14.		Mohnyin	2012	515	0	515
15,16		Hpakan, Seikmu	2012/2013	1108	57	1165
17		Lonekhin	2014	676	10	686
18		Mansi	2015	104	0	104
19		Shwegu	2015	75	3	78
20		Chipwi	2016	9	0	9
21		Momaauk	2016	113	2	115
22	Shan (North)	Lashio	2006	344	3	347
23		Hseni	2012	63	1	64
24		Kutkai	2011	137	1	138
25		Muse	2010	296	6	302
26		Nanhkan	2011	212	2	214
27		Namphatka	2013	49	2	51
28		Kyaukme	2013	154	1	155
29		Tamoenye	2014	39	2	41
30		Namtu	2014	81	0	81
31		Nampaung	2014	53	2	55
32		Tangyan	2015	96	2	98
33		Namhsan	2015	7	0	7
34		Hsipaw	2016	84	1	85
35		Nawngkhio	2017	29	0	29
36		Mongmit	2017	99	0	99
37	Shan (East)	Tachileik	2010	137	10	147

38	Sagaing	Sagaing	2013	197	0	197
39		Monywa	2013	41	0	41
40		Kale	2013	212	2	214
41		Kawlin	2013	247	1	248
42		Pinlebu	2014	407	1	408
43		Katha	2014	169	1	170
44		Tamu	2014	150	6	156
45		Hkamti	2014	218	5	223
46,47		Homalin/ Naungpoaung	2014/2017	357	3	360
48		Banmauk	2014	208	0	208
49		Paungbyin	2016	224	0	224
50,51		Indaw/Mawlu	2016/2017	572	3	575
	Total			13246	195	13441

* Naungpoaung data was combined with Homalin data as it is under Homalin Township administration. Similarly, Mawlu data was combined with Indaw data.

Methadone dispensing sites were increased gradually based on availability of funds and it could be seen as below;




Figure 3: Expansion of MMT sites by year




Figure 4: MMT clients (Daily active) against MMT sites (2006 – 2017)

Methadone centers and density of Methadone patients in Myanmar 2017




Figure 5: Current methadone maintenance treatment sites in Myanmar by Region/States with caseload

Methadone clients by Region/States




Figure 6: Methadone patients in Mandalay Region




Figure 7: Methadone patients in Kachin State




Figure 8: Methadone patients in Shan State




Figure 9: Methadone patients in Sagaing Region



Advocacy event to launch MMT center in Nawngkhio of Northern Shan State




A methadone patient visiting to receive daily medication at Hseni

3. Integrated services of MMT

In 2014, other components of comprehensive package for PWIDs were integrated into MMT program to be able to contribute more to national response to HIV problem. According to Integrated Biological and Behavioral Surveillance in 2014⁸, HIV prevalence in study sites were seen as below;

Figure 57. HIV prevalence among male PWID respondents - IBBS and HSS results



Denominator: All male respondents

Figure 10: HIV prevalence among male PWID respondents

Integrated services included HIV testing service (HTS); anti-retroviral therapy (ART); condom distribution program for PWID and their sexual partners; targeted information, education and communication (IEC) for PWID and their sexual partners; Hepatitis B Virus (HBV) Testing and Vaccination; and Hepatitis C Virus (HCV) Test, prevention, diagnosis and treatment of tuberculosis (TB); and detection and management of sexual transmitted infections (STI).

Achievements of integrated services (Table 11)

Achievements by indicators ⁹	Male	Female	Total
Number of MMT patients who received an HIV test and who know the result	5298	96	5394
Number partners of MMT patients who received an HIV test and who know the result	8	72	80
Number of MMT patients who received HBS Antigen rapid test	4562	73	4635
Number of MMT patients who received vaccination with rapid schedule for Hepatitis B infection	1368	17	1385
Number of MMT patients who received Hepatitis C test (HCV Antibody)	4178	48	4226
Other achievements by activities			
Number of IEC materials distributed to PWIDs			22725
Number of condoms distributed to PWIDs			124160
Number of PWIDs referred for ART			656
Number of PWIDs referred for STI			105
Number of PWIDs referred for TB			249
Number of drug abuse prevention pamphlets distributed			3089
Number of drug abuse prevention pamphlets distributed			1218



Taking blood sample from a client for blood test at
Nawngkhio MMT clinic



Awareness raising on drug abuse at Tangyan, Northern Shan State

4. Meeting and Workshops

- Workshops on development of "National Drug Control Policy"
 - (a) National Expert Group review meeting on "Development of Drug Control Policy in Myanmar (6-7 June 2017)
 - (b) Meeting on endorsement of National Drug Control Policy in Myanmar (23 November 2017)
- Advocacy meeting in Kale for Community Based Drug Treatment (16 December 2017)
- Meeting with Township Steering Committee in Kale (16 December 2017)
- Drug User Working Group meeting (8 August 2017, 30 October 2017)
- Workshop on methadone guideline review (22 September 2017)
- Expert Working Group Meeting to review UTC 6&7 of Colombo Plan (25-27 April 2017)



Township Steering Committee Meeting in Kale



Expert Working Group Meeting of Colombo Plan
in Yangon

5. Capacity development

In 2017, review of methadone therapy and drug dependency treatment guideline which was printed in 2012 was revised and others were developed as below;

1. Guidelines on Methadone Therapy and Treatment of Drug Dependence in Myanmar (Revision)
2. Standard Operating Procedures for Methadone Maintenance Therapy (October 2017)
3. Guidelines for the management of Methamphetamine Use Disorders in Myanmar (November 2017)

Training sessions organized by DDTRU (Table 12) could be seen as below;

No.	Title	Place	Date	Participants
1.	Training on Drug Abuse Prevention and Treatment including MMT	Mandalay	15-17 February 2017	49
2.		Myitkyina	22-24 May 2017	45
3.		Lashio	11-13 September 2017	55

4.	Training for Counseling in MMT	Mandalay	20-21 February 2017	55
5.		Myitkyina	25-27 May 2017	47
6.		Lashio	14-16 September 2017	52
7.	Training workshop on drug abuse prevention and treatment including MMT	Myeik	24-25 August 2017	32
8.	Training workshop on management of substance use disorder including community-based drug treatment	Hpa-An	29-30 August 2017	31



Training on Drug Abuse Prevention and MMT in Myitkyina



Training on substance use disorders including community based treatment in Hpa-An



Commander of Drug Enforcement Division providing opening remarks at ToT workshop on community based services in Myanmar

6. Research activities

Research and assessment activities done in 2017 were as follows;

1. Way forward for Methadone Maintenance Treatment (MMT) Program: Looking at a glance at a high burden area (Nanda Myo Aung Wan, Kyaw Lwin Show, Yin Thet Nu Oo, Le Le Win, Kyaw Thu Hein; DDTRU and Department of Medical Research)
2. Analysis of Methadone programme data, client profile, treatment outcomes, referrals and linkages to antiretroviral treatment and TB care among drug users in Myanmar – generating Myanmar-specific evidence on retention in treatment and referral to care (DDTRU and WHO)
3. Mapping of Substance Abuse Treatment and Care Facilities (DDTRU and UNODC)

Collaboration with stakeholders

- UN agencies: WHO, UNODC, UNAIDS, UNOPS
- Colombo Plan: International Centre for Credentialing and Education of Addiction Professionals (ICCE) initiatives in Myanmar
- NGO/INGOs working for harm reduction: Asian Harm Reduction Network (AHRN), Burnet Institute (BI), Health Poverty Action (HPA), Medicine du Monde (MDM), Myanmar Anti-Narcotic Association (MANA), Substance Abuse Research Association (SARA)

Project Manager of DDTRU also acted as the chairperson of Drug User Working Group (DUWG). DUWG was formed of representatives from CCDAC, NAP, UN agencies (UNODC, UNAIDS, WHO) and NGO/INGOs working for harm reduction. It was an important body under Technical Strategic Group on HIV and DUWG was also important for coordination of harm reduction activities at operational level.

NGO/INGOs working for harm reduction across the country collaborated and worked together with MMT program at field level to be able to implement program successfully.



Opening event of Colombo training on addiction treatment



Myanmar - Thailand workshop on drug treatment and rehabilitation held in Mandalay

Conclusion

Drug use problem was a big threat to the development of the country. Along with policy changes in the country, DDTRU played the leadership role to initiate community based drug treatment program in some areas of the country in collaboration with UNODC in 2017 and also participated in developing 'National Drug Control Policy'. DDTRU also expanded MMT program and opened five new sites in drug use prevalent areas to improve access as well as availability of services in this year.

Changing trends of drug use along with poor knowledge on drug use as well as desire to try new things were challenges to drug treatment sector with resource limitations. As methadone clients had to visit to dispensing site daily routinely, it was also a challenge for clinical staff with increasing number of clients as well as subsequent increase in workload. In 2017, two automatic dispensing machines were installed at Yangon and Mandalay centers and workload related to daily dispensing activities might be reduced if automatic machines could be installed at methadone clinics more and more in the future. However, DDTRU worked together with its teams and partners to reach planned goals.

Annexes

Annex 1: Summary of Notifications issued by Ministry of Health & Sports

Notification	Subject/Items
1/2002	Control of precursor chemicals (Schedule I, II, III) as per 1988 Convention
2/2002	Psychotropic substances as per 1971 Convention (Schedule I,II,III,IV,V)
3/2002	Narcotic drugs as per 1961 Convention (Schedule I, II, III)
4/2002	Announcement of major drug treatment centres
5/2002	Announcement of minor drug treatment centres
1/2004	Amineptine was added to psychotropic substances as per 1971 Convention (Schedule II)
1/2005	Zolpidem and Ketamine were added to psychotropic substances as per 1971 Convention (Schedule IV)
2/2005	Myragyna Speciosa and Tramadol were added to narcotic drugs as per 1961 Convention (Schedule III)
6/2010	Safrole rich oil was added to Schedule I of 1988 Convention Drugs
10/2012	Myragyna Speciosa (Kratom): Dry leaves/powder 1.5 Kg and above, wet leaves 6 Kg and above shall be deemed to possess for the purpose of sale and to transport, transmit or transfer for the purpose of sale.

Annex 2: Structure and functions of Drug User Working Group

Designation	Ministry/Department/Organization
Chair	Program Manager of DDTRU
Co-chair	Representative from CCDAC
Members	NAP (Department of Public Health), Department of Social Welfare, UNAIDS, WHO, AHRN, BI, HPA, MANA, MDM, National Drug User Network Myanmar(NDNM), AIDS Alliance, Save the Children – PR, UNOPS – PR, 3MDG, Drug Policy Advocacy Group (DPAG), PSI and Sao Mon, SARA

Functions of DUWG

1. Provide technical input in the development of National Strategic Plan, operational Plan and provide inputs on costing as well as Legal and Policy reform related to drug issue
2. Provide support to TSG on the drug related issues such as;
 - (a) Contribute in development / revision of guidelines
 - (b) Scale up harm reduction interventions
3. Assist the setting up and strengthening of country wide Drug User Networks, establishing links through various partners
4. Coordinate with the other working groups such as care and support, mobility, youth, PMTCT, OVC and Sex Worker working group, etc.
5. To facilitate the provision of up-to-date data on key indicators and coverage information- which will help to identify gaps in provision of quality services and strengthen the existing services, problem of HIV and drug use, results/impacts of interventions

6. Designing and carrying out research such as operational research, denominator population exercise, behavioral studies etc.
7. Developing advocacy initiatives where necessary, relating to policy or operational issues, and policy papers related to harm reduction

References:

¹ World Drug Report, UNOD (2016)/(2017)

² 2016 Annual Report of CCDAC

³ Report of the HIV Sentinel Sero-surveillance Survey, 2008: NAP, DoH Myanmar

⁴ Technical Guide for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users; WHO, UNODC, UNAIDS

⁵ National Guidelines: A Core Package for HIV Prevention amongst Key Populations in Myanmar, October 2014: NAP, DoH, Ministry of Health

⁶ Notification 3/2016, CCDAC, Ministry of Home Affairs

⁷ The 2014 Myanmar Population and Housing Census: Thematic Report on Children and Youth, Census report volume 4-M, Department of Population, Ministry of labor, Immigration and Population, Myanmar.

⁸ Myanmar Integrated Biological and Behavioral Surveillance Survey and Population Size Estimates among People Who Inject Drugs 2014, Ministry of Health and Sports Myanmar

⁹ National Strategic Plan on HIV and AIDS Myanmar (2016-2020)

